Koru Medical (KRMD) Q3 2026: Profit Beat Powered by Margin Surge

Koru Medical Systems swung to a profit in Q3 2026 that Wall Street had not expected, reporting adjusted earnings per share of $0.02 against a consensus estimate of negative $0.02. Revenue of $11.57 million edged past the $11.33 million estimate by about 2% and grew 11.2% year over year, but the 200% beat came mainly from a sharp improvement in the company's cost structure.

The headline driver was gross margin, which expanded to 65.2% from 60.2% a year earlier. Lower manufacturing costs, a favorable geographic mix that lifted average selling prices, and tariff-related rebates that reduced input costs all contributed. The result was GAAP net income of $218,103, compared with a net loss in the same quarter of 2025, and adjusted EBITDA climbed to $1.31 million.

This marks the second consecutive quarter of positive net income and positive adjusted EBITDA, a milestone CEO Adam Kalbermatten called evidence of the scalability of the business model. The streak matters for a small-cap medical device company that has spent years posting losses, because it signals the revenue base is now large enough to consistently cover operating costs.

Revenue growth did moderate from the first-half pace, partly because of the timing of Koru's entry into a competitive non-tender market in Europe. With that launch now complete, management expects growth to reaccelerate in Q4. The company also signed two new sales and distribution agreements with partners in Europe and Africa during the quarter.

Management tightened full-year 2026 revenue guidance to $48.0 million to $48.5 million, implying 17% to 18% year-over-year growth, narrowing from the prior range of $47.5 million to $48.5 million. It also raised its year-end cash target to above $8.0 million from above $7.5 million previously, a meaningful signal for a company whose cash balance stood at $7.4 million at quarter end.